 |
|
A new step towards an AIDS vaccine
October 14, 2005Progressive disease after HIV infection is inversely correlated with the presence of plasmacytoid dendritic cells (pDCs), a subset of the dendritic cell family and the major producers of type 1 interferon in the body. High numbers of pDCs is related to successful control of HIV. In a paper appearing online on October 13 in advance of print publication of the November issue of the Journal of Clinical Investigation, Nina Bhardwaj and colleagues from New York University report the mechanisms by which HIV-1 activates human pDCs.
The authors show that pDC activation by HIV-1 requires at least two interactions between the cell and virus. Initially, envelope-CD4 interactions mediate the endocytosis of HIV-1. Next, viral nucleic acids, particularly RNA, stimulate pDCs through Toll-like receptors.
A decrease of blood pDC frequency is typically observed in chronic infections due to HIV-1 and correlates with high viral load, reduced CD4 counts and susceptibility to opportunistic infections, and is only partially reverted by anti-retroviral therapy. By identifying the active component of HIV-1 which stimulates pDC function, and consequently other antigen presenting cell function, the authors have recognized an important pathway whereby DC function can be targeted in the design of efficient vaccines or immunotherapies for HIV.
Journal of Clinical Investigation
Journal of Clinical Investigation
AIDS Vaccine Current Events and AIDS Vaccine News RSSScientists use world's fastest supercomputer to create the largest HIV evolutionary tree
Supporting Los Alamos National Laboratory's role in the international Center for HIV/AIDS Vaccine Immunology (CHAVI) consortium, researchers are using the Roadrunner supercomputer to analyze vast quantities of genetic sequences from HIV infected people in the hope of zeroing in on possible vaccine target areas.
Caltech scientists show why anti-HIV antibodies are ineffective at blocking infection
Some 25 years after the AIDS epidemic spawned a worldwide search for an effective vaccine against the human immunodeficiency virus (HIV), progress in the field seems to have effectively become stalled.
HIV Adapts to 'Escape' Immune Response
The human immunodeficiency virus (HIV) adapts so well to the body's defense system that any successful AIDS vaccine must keep pace with the ever-changing immunological profile of the virus, according to researchers at the University of Alabama at Birmingham (UAB) and the University of Oxford in England.
How much is the world spending on neglected disease research and development?
The first comprehensive survey of global spending on neglected disease R&D, published in this week's PLoS Medicine, finds that just over $US 2.5 billion was invested into R&D of new products in 2007, with three diseases-HIV/AIDS, TB, and malaria-receiving nearly 80% of the total.
Nature Medicine study shows Peregrine's bavituximab can cure lethal virus infections
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM) today reported publication of data in Nature Medicine that supports the broad anti-viral potential of the company's novel anti-phosphatidylserine (anti-PS) antibody platform, showing that its PS-targeting drug bavituximab can cure lethal virus infections in animal disease models.
T cell-based HIV vaccine candidate demonstrates positive results
The question of whether or not to continue to pursue the development of T-cell-based HIV-1 vaccines has been a source of controversy following last year's widely publicized failure of the field's most promising candidate, a vaccine developed by Merck known as V520.
Personalized immunotherapy to fight HIV/AIDS
For a long time, the main obstacle to creating an AIDS vaccine has been the high genetic variability of the HIV virus. Dr. Jean-Pierre Routy and his team from the Research Institute of the McGill University Health Centre (MUHC), in collaboration with Dr. Rafick Sékaly from the Université de Montréal, have overcome this difficulty by designing a personalized immunotherapy for HIV-infected patients.
India continues to progress in AIDS vaccine development efforts
A second Phase I AIDS vaccine clinical trial in India was successfully completed, the Indian Council of Medical Research, the National AIDS Control Organization and the International AIDS Vaccine Initiative announced. The results of the trial of an MVA-based AIDS vaccine candidate (TBC-M4), which was conducted in Chennai, indicated that the vaccine candidate had acceptable levels of safety and was well tolerated.
HIV conquers immune system faster than previously realized
New research into the earliest events occurring immediately upon infection with HIV-I shows that the virus deals a stunning blow to the immune system earlier than was previously understood.
UT Pathologists Believe They Have Pinpointed Achilles Heel of HIV
Human Immunodeficiency Virus (HIV) researchers at The University of Texas Medical School at Houston believe they have uncovered the Achilles heel in the armor of the virus that continues to kill millions.
More AIDS Vaccine Current Events and AIDS Vaccine News Articles
 |
Shots in the Dark: The Wayward Search for an AIDS Vaccine by Jon Cohen (Author) "[A]n important book not only for the now but for the future of this epidemic and those to come."—Dr. Robert Gallo When scientists proved in 1984 that HIV causes AIDS, a vaccine race spun into action. But the sprint to develop an AIDS vaccine now more closely resembles a crawl. Jon Cohen elucidates the forces that have hindered the search: unforeseen scientific obstacles, clashing personalities, the uncertain marketplace, haphazard political organization, and serious ethical dilemmas. Beyond a powerful critique, Cohen also offers specific recommendations for accelerating the effort. 6 pages of b/w photographs.. |
 |
2009 Upper Deck Historic Predictors #HP-8 First AIDS Vaccine is Developed (Baseball Cards) by Baseball Cards 2009 Upper Deck Historic Predictors #HP-8 First AIDS Vaccine is Developed (Baseball Cards) |
 |
Ending Aids: The Search for a Vaccine KQED / PBS documentary production narrated by Richard Gere. |
|
AIDS vaccine handbook; second edition: global perspectives. by Patricia, ed Kahn (Author) | |
 |
Teaching About Immunity Kit by American Educational Products This kit clearly displays the interrelated workings of the Immunity System. Attack an invading anigen with a phagocyte or monbyte. Produce macrophages. T-Cells, B-Cells, Plasma Cells, and antibodies. Clone T and B cells to produce Helper, Killer, Memory and Suppression cells. Demonstrate the operation of AIDS, Cancer, Vaccines, Allergies, Autoimmune reactions and more right on the board. Students can readily participate in the "hands on" activities. The Plastick pieces will not break, chip, tear, peel or wear out! Comes complete with a 30" X 40" Demonstration Board, mounting legs, and Teacher's Guide with detailed lesson plans plus reproducible student worksheets. |
|
2009 Upper Deck 8 AIDS Vaccine Historic First Predictors Baseball Card | |
 |
AIDS Vaccine Development: Challenges and Opportunities by Wayne C. Koff (Editor), Patricia Kahn (Editor), Ian D. Gust (Editor) |
 |
Charlie Rose with Donald Francis; Richard Price; David Rockwell; Jewel (June 3, 1998) First, Dr. Donald Francis, AIDS pioneer researcher of the company Vaxgen, discusses the new FDA approval for human testing for a vaccine against AIDS and talks about the disease in general. Then, Richard Price, known as "the voice of the Bronx," discusses his new book Freedomland, set in a fictional New Jersey town. Then, David Rockwell discusses his field of business, the burgeoning market "entertainment architecture" which creates elaborate theme-style restaurants, hotels, zoos, and more. Finally, singer Jewel discusses her new book of poetry, A Night Without Armor, and reads some excerpts of that work. This product is manufactured on demand using DVD-R recordable media. Amazon.com's standard return policy will apply. |
|
Vaccines 92: Modern Approaches to New Vaccines Including Prevention of AIDS by Fred Brown (Author), Robert M. Chanock (Author), Harold S. Ginsberg (Contributor) | |
|
AIDS vaccine may reduce rate of infection: greater efficacy in nonwhites.(Clinical Rounds): An article from: Clinical Psychiatry News by Nancy Walsh (Author) This digital document is an article from Clinical Psychiatry News, published by International Medical News Group on August 1, 2003. The length of the article is 423 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser. Citation Details Title: AIDS vaccine may reduce rate of infection: greater efficacy in nonwhites.(Clinical Rounds) Author: Nancy Walsh Publication: Clinical Psychiatry News (Magazine/Journal) Date: August 1, 2003 Publisher: International Medical News Group Volume: 31 Issue: 8 Page: 50(1) Distributed by Thomson... |
| © 2009 BrightSurf.com |